Moorestown, New Jersey, United States
BiotecHeart™
Coming Soon -
BiotecHeart™ - See The Light
BiotecHeart™ - See The Light
Feb. 20, 2020 10:20 AM ET|About: Amarin Corporation plc (AMRN), BMY, DBX, GILD, JNJ, MRK, NVO, NVS, PFE, RHHBY, ABBVSummary
The political and socio-economic environment in America, is both depressing and disconcerting.
The hostility increases towards everyone connected with the biotech/drug industry during this highly politically charged season.
Politicos still see little to no value in biotech companies and continue to vilify them.
There continues to be much encouraging news and positive clinical tests in the biotech world, including on the coronavirus situation, for the first 2 months of 2020.
BiotecHeart™ Joy Unto The World
BiotecHeart™ Joy Unto The World
Dec. 24, 2019 6:31 AM ET|About: AbbVie Inc. (ABBV), ABMD, ABT, AMGN, AMRN, AZN, BGNE, BIIB, BLUE, BMRN, BMY, GILD, ISRG, JNJ, LLY, MDT, MRK, NVS, PFE, REGN, RHHBY, SGEN, SRPT, VRTXSummary
this has been the “Biotech Decade” 2010-2019.
this year has been the “Biotech Year”.
Based on the current political environment it has been a spectacular year for the healthcare sector, and for many biotech companies.
Welcome to BiotecHeart™
BiotecHeart will highlight product development progress
* pipelines/life-lines and research & development efforts
* product presentations that involve clinical development progress
* clinical trials that are seeking volunteers for new meds
* product presentations that are presented at key meetings/conferences
Thank you visiting www.biotecheart.com
BiotecHeart™ - See The Light
danwatson888's Blog long only, Deep Value, dividend growth investing, healthcare
BiotecHeart™ - See The Light
Feb. 20, 2020 10:20 AM ET|About: Amarin Corporation plc (AMRN), BMY, (BDX), GILD, JNJ, MRK, NVO, NVS, PFE, RHHBY, ABBV
Summary
The political and socio-economic environment in America, is both depressing and disconcerting.
The hostility increases towards everyone connected with the biotech/drug industry during this highly politically charged season.
Politicos still see little to no value in biotech companies and continue to vilify them.
There continues to be much encouraging news and positive clinical tests in the biotech world, including on the coronavirus situation, for the first 2 months of 2020.
BiotecHeart™ - See The Light
BiotecHeart™ - See The Light
Feb. 20, 2020 10:20 AM ET|About: (AMRN), BMY, BDX, GILD, JNJ, MRK, NVO, NVS,
Summary
The political and socio-economic environment in America, is both depressing and disconcerting.
The hostility increases towards everyone connected with the biotech/drug industry during this highly politically charged season.
Politicos still see little to no value in biotech companies and continue to vilify them.
BiotecHeart™ - See The Light
https://seekingalpha.com/instablog/5205071-danwatson888/5411014-biotecheart-see-light
There continues to be much encouraging news and positive clinical tests in the biotech world, including on the coronavirus situation, for the first 2 months of 2020.
danwatson888
long only, Deep Value, dividend growth investing, healthcare
BiotecHeart™ “Joy Unto The World”
Dec. 24, 2019 6:27 AM ET
Summary
this has been the “Biotech Decade” 2010-2019.
this year has been the “Biotech Year”.
Based on the current political environment it has been a spectacular year for the healthcare sector, and for many biotech companies.
BiotecHEART™-Breakthrough
Dec. 9, 2019 8:35 AM ET|About: AbbVie Inc. (ABBV), ALPMY, BMY, CELG, JNJ, MRK, PFE, RHHBY, SGEN
Summary
There is no impossible.
2019, has been a breakthrough year for all who need medicine.
many clinical tests involving combinations of successful medicines.
many approvals this year in China for successful medicines.
BiotecHeart™
Jan 14, 2019,07:44am EST|13,441 views
2018 New Drugs Approvals: An All-Time Record, And A Watershed
Bernard Munos Former Contributor Healthcare
This article is more than 2 years old.
Moderna’s Fully Enrolled Phase 3 COVE Study of mRNA-1273
Enrollment Complete
30,000 participants enrolled
in the COVE Phase 3 Study as of Thursday, October 22, 2020.
25,654 participants have received their second vaccination.
View Demographic Data for the Phase 3 COVE Study
View the Phase 3 COVE Study Protocol
life-lines
bluebird bio, Inc. (BLUE)
SAGE - Sage Therapeutics, Inc.
bluebird bio, Inc. (BLUE)
MRNA - Moderna, Inc.
SAGE - Sage Therapeutics, Inc.
bluebird bio, Inc. (BLUE)
SAGE - Sage Therapeutics, Inc.
SAGE - Sage Therapeutics, Inc.
SAGE - Sage Therapeutics, Inc.
Pipeline
Advancing a Leading Brain Health Portfolio
Our differentiated approach to drug discovery and development has allowed us to create a broad portfolio of fully-owned product candidates with the potential for development in a wide range of psychiatric, neurological and related central nervous system (CNS) disorders.
ZYME - Zymeworks Inc.
ICPT - Intercept Pharmaceuticals, Inc.
SAGE - Sage Therapeutics, Inc.
We currently have two wholly-owned product candidates in clinical development and several wholly-owned product candidates in preclinical development that leverage our multiple therapeutic platforms to address areas of significant unmet medical need.
ICPT - Intercept Pharmaceuticals, Inc.
ICPT - Intercept Pharmaceuticals, Inc.
ICPT - Intercept Pharmaceuticals, Inc.
PIPELINE
Novel compounds being developed for liver diseases
CRSP - CRISPR Therapeutics AG
ICPT - Intercept Pharmaceuticals, Inc.
ICPT - Intercept Pharmaceuticals, Inc.
. We have established a portfolio of programs by selecting disease targets based on a number of criteria, including unmet medical need, technical feasibility, advantages of CRISPR/Cas9 relative to other approaches and time required to advance the product candidate into and through clinical trials.
life-lines
SRPT
SRPT
SRPT
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular dystrophy (DMD) and more recently in gene therapies for six Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth (CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.
ALXN
SRPT
SRPT
We’re building on our fundamental understanding of complement biology and advancing on our core therapeutic areas of hematology, nephrology, neurology, metabolics, and cardiology. We continue to evolve into new areas where there is great unmet need and opportunity to help people living with rare diseases and their families fully live their best lives.
NKTR
SRPT
TSE Code 4502
Nektar Therapeutics has a deep and diverse portfolio of investigational medicines in different stages of clinical development. We are focused on using new chemistry approaches to make better medicines to treat cancer, chronic pain and auto-immune disease.
Nektar Therapeutics also has a number of strategic partnerships ranging from joint discovery and co-development to licensing and royalty arrangements with numerous companies.
TSE Code 4502
Private company
TSE Code 4502
We are committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. We focus on our R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Disease. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.
Key Products and Pipeline (FY2019 Q2 Pipeline Table)
SNY
Private company
Private company
As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority.
Private company
Private company
Private company
Boehringer Ingelheim is clear about its goals. We want to deliver a portfolio of breakthrough medicines that will improve the lives of patients around the word. That starts with innovation. With a pipeline of around 90 clinical and pre-clinical projects, with the potential to deliver up to 15 new medicines by 2025, we continue our track record of long-term innovation-led performance.
life-lines
AVEO
AVEO
AVEO
AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is seeking to develop and commercialize in North America as a treatment for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and other cancers. Tivozanib (FOTIVDA®) is approved by the European Commission for the treatment of adult patients with advanced RCC in the European Union plus Norway, New Zealand and Iceland. AVEO is leveraging or seeks to leverage partnerships to develop and commercialize its pipeline of products and product candidates, including tivozanib in oncology and other indications in various geographies, and ficlatuzumab (HGF MAb) in head and neck cancer, pancreatic cancer and acute myeloid leukemia. AVEO’s earlier-stage pipeline includes AV-203 (anti-ErbB3 MAb), AV-380 (GDF15 MAb) and AV-353 (Notch 3 MAb) drug candidates being developed for various oncology indications.
KRTX
AVEO
AVEO
Our pipeline is built on the broad therapeutic potential of our lead product candidate, KarXT, an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. KarXT is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the CNS.
ALNY
AVEO
ALNY
Alnylam is leading the translation of RNAi (RNA interference) into a whole new class of innovative medicines to potentially address the needs of patients who have limited or inadequate treatment options. Our pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need that fall under 4 Strategic Therapeutic Areas (STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS) and ocular diseases. .
HRTX
HRTX
ALNY
We are currently developing and commercializing pharmaceutical products for patients suffering from cancer or postoperative pain. Our goal is to develop each of our products with patients' needs at the center of our focus, and to deliver products with best-in-class therapeutic potential.
VCYT
HRTX
VCYT
PIPELINE
Our product pipeline expands on our founding strategy to improve diagnostic accuracy by answering clinical questions in our indications further across the clinical care continuum, including early detection and informing treatment decisions. We also continue to evaluate intellectual property and corporate acquisitions that we believe answer clinically meaningful questions and enable better patient outcomes. We believe the global market opportunity for our products is over $30 billion annually.
NBIX
HRTX
VCYT
Pipeline Overview
life-lines
MRK
RHHBY
BIIB
Scientific curiosity drives us to invent solutions to some of the world's most challenging diseases.
Many begin in Merck Research Laboratories (MRL), where we focus on discovering and developing therapies to improve patients' lives.
RHHBY
RHHBY
RHHBY
Pipeline summary Marketed products additional indications Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED (Genentech Research & Early Development)
https://www.roche.com/dam/jcr:4fcd49b1-bcd5-4714-96ed-2589d7413548/en/irp180426-annex.pdf
PIPELINE
https://www.gene.com/medical-professionals/pipeline
Roche Holding (RHHBY) Presents At 2019 ASH Annual Meeting - Slideshow
Dec. 10, 2019 2:42 PM ET | About: Roche Holding AG (RHHBY)
LLY
LLY
RHHBY
MEDICINES IN DEVELOPMENT
MOLECULE & POTENTIAL INDICATION DATA AS OF OCTOBER 21, 2019
Interested in Lilly clinical trials? Learn more at LillyTrialGuide.com
https://www.lilly.com/discovery/pipeli
AMGN
LLY
AMGN
A robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illness. Amgen is focused on high-quality candidates that demonstrate large, clinically-relevant effects. Human genetic validation is used whenever possible to enhance the likelihood of success.
AZN
LLY
AMGN
AstraZeneca plc (AZN) Presents At 2019 ASH Annual Meeting - Slideshow
Dec. 11, 2019 8:53 AM ET | About: AstraZeneca PLC (AZN)
life-lines
CELG
LOXO
CELG
BMY
LOXO
CELG
In The Pipeline
Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients.
https://www.bms.com/researchers-and-partners/in-the-pipeline.html
LOXO
LOXO
LOXO
PFE
REGN
LOXO
PRODUCT PIPELINE
OUR MEDICINES IN DEVELOPMENT
Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients.
REGN
REGN
REGN
Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
https://www.regeneron.com/pipeline
NVS
REGN
REGN
Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day
Dec 05, 2019
Novartis R&D Day London, UK December 5, 2019
life-lines
GILD
GILD
GILD
Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.
ABBV
GILD
GILD
Advanced medicines that demonstrate both strong clinical performance and strong economic value
(Select pipeline highlights as of January 2019)
JNJ
GILD
BMRN
SELECTED PHARMACEUTICALS IN LATE STAGE U.S. AND E.U. DEVELOPMENT OR REGISTRATION as of 10/15/19
http://www.investor.jnj.com/_document/jnj-pipeline-q3-2019?id=0000016d-cf32-dfd4-a36f-df3f71d90000
BMRN
BMRN
BMRN
BioMarin has developed and commercialized a growing list of innovative biopharmaceuticals for rare diseases driven by genetic causes since 1997, a testament to the company’s passion and dedication to patients with serious unmet medical needs.
https://www.biomarin.com/products+and+pipeline+overview
VRTX
BMRN
VRTX
A Pathway to the Future
We’re focused on developing transformative medicines for people with serious and life-threatening diseases.
SGEN
BMRN
VRTX
Strong Development Pipeline
A diverse pipeline designed to address significant unmet medical needs
We are focused on developing a new generation of targeted, empowered therapies with the goal of advancing the foundation of care. In addition to a comprehensive development program to further expand ADCETRIS® (brentuximab vedotin), our robust pipeline is designed to address significant unmet medical needs.
The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
life-lines
EXEL
EXEL
EXEL
The Exelixis pipeline includes our lead compounds, cabozantinib and cobimetinib, as well as other programs that are the subject of partnerships and collaborations with several biopharmaceutical companies. An additional wholly owned compound, XL888, is the subject of ongoing clinical research through our Investigator-Sponsored Trial program. Safety and efficacy for these compounds in the unapproved uses or indications described below have not yet been established.
https://www.exelixis.com/pipeline/
AGN
EXEL
EXEL
Allergan is focused on driving innovation in four core therapeutic areas. As part of our approach to delivering innovation for better patient care, we have built one of the broadest pharmaceutical and device research and development pipelines in the industry.
https://www.allergan.com/research-and-development/pipeline
BGNE
EXEL
BGNE
BeiGene
Pipeline
We are advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. We have three internally-developed late-stage clinical drug candidates and three marketed products in China.
https://www.beigene.com/science-and-product-portfolio/pipeline
XON
SGMO
BGNE
We are a community of scientists and creative innovators working to build a safer, healthier planet, and a more promising future.
Our unique expertise is in the design and engineering of astonishing living systems, from T-cells that battle cancer to non-browning apples. Across our diverse portfolio of projects we apply a common philosophy: bring together the greatest minds in synthetic biology and empower them to solve big problems.
We’re developing solutions through intrexon Health and intrexon Bioengineering. intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency.
SGMO
SGMO
SGMO
HERAPEUTIC PROGRAMS UNDER DEVELOPMENT
Our strategy is to retain and develop product candidates ourselves in certain therapeutic areas that meet key criteria including having breakthrough potential for unmet needs; where development and commercialization are financially and operationally feasible; and where we see synergies across our product candidates and therapeutic approaches.
We are focusing our proprietary pipeline on research and development of product candidates for inherited metabolic diseases, central nervous system diseases, and immunology.
Collaboration is critical to maximizing the value of our platform technology and has brought important funding and expertise to our research. We will continue to collaborate, especially in therapeutic areas that are highly competitive or that require special disease area expertise or resources.
NVO
SGMO
SGMO
We discover, develop and deliver
We are passionate about translating patients' unmet medical needs into novel ideas for therapeutic solutions. As a global provider of advanced treatments for diabetes and other serious chronic diseases, our goal is always to discover and develop innovative biological medicines and make them accessible to patients throughout the world.
https://www.novonordisk.com/research-and-development/our-therapy-areas.html
Accessing your medicines can be confusing. It doesn’t have
About MAT.org PhRMA’s Medicine Assistance Tool (MAT) is a search engine designed to help patients, caregivers and health care providers learn more about the resources available through the various biopharmaceutical industry programs. MAT is not its own patient assistance program, but rather a search engine for many of the patient assistance resources that the biopharmaceutical industry offers.
.
Authorized generics of NovoLog® and NovoLog Mix®
Novo Nordisk's new insulin affordability offerings now available in the US
https://www.novonordisk-us.com/
Novo Nordisk's new insulin affordability offerings now available in the US
Bernard Munos Contributor
Jan 14, 2019, 07:44am Bernard Munos Contributor
2018 New Drugs Approvals: An All-Time Record, And A Watershed
Bernard Munos Contributor
I study pharmaceutical innovation, what causes it and how to get more of it. Several of my papers, published in Nature and Science, have helped stimulate a rethinking of the industry business model. In 2012, the popular newsletter FiercePharma named me one of the 25 most influential people in biopharma. In 2013, I became a Senior Fellow at FasterCures (a center of the Milken Institute). Besides doing research, I spend a lot of time helping organizations – big, small, public, private, US and non-US – become better innovators. I learned my trade in the 30 years I spent in the industry at Eli Lilly. Before that, I trained as an animal scientist in France and earned additional degrees in business and economics from Stanford and UC-Davis. I serve on various boards and advisory bodies, including at NCATS, the Institute of Medicine, Glenmark Pharmaceuticals, think tanks and foundations.